Saturday 17 October 2026
Export CRDL’s income statement to Excel — free account
Cardiol Therapeutics Inc.
CRDL Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, EPS grew 42.9%, free cash flow grew 10.6% and total debt fell 38.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.10
0.05
−4.35%
Follow CRDL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(375.38%) | (156.96%) | (159.27%) | (171.13%) | |
| (246.19%) | (120.54%) | (117.20%) | (124.40%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(390.50%) | (188.25%) | (134.49%) | (127.30%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.21) | (0.20) | (0.16) | (0.15) | |
Free Cash Flow |
(17.56) | (17.09) | (17.61) | (17.24) | |
Capital Expenditures |
(0.02) | (0.02) | (0.04) | (0.04) | |
| Other line items | |||||
Cash ROIC |
(113.69%) | (60.64%) | (46.51%) | (47.58%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.64 | 0.71 | 0.74 | 0.78 | |
Depreciation/Fixed assets |
0.88 | 0.86 | 0.74 | 0.68 | |
Capex/Depreciation |
(0.22) | (0.24) | (0.58) | (0.64) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.21) | (0.20) | (0.16) | (0.15) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates